Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia ID6519Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 14 October 2026
Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC